April 1, 2021 06:59 AM EDTUpdated April 2, 01:13 PM

US special counsel looks into alleged misconduct at Merck plant prepping to make J&J shot — and indifference from FDA

Josh Sullivan

The US Office of Special Counsel has unveiled the details of a whistleblower complaint from a former FDA employee who alleged numerous violations at a …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

US special counsel looks into alleged misconduct at Merck plant prepping to make J&J shot — and indifference from FDA

Josh Sullivan

Sign up to read this article for free.

Exclusive: Athena Countouriotis' Avenzo taps Shanghai biotech for ADC, adds new funds

Merck finally has subcutaneous Keytruda results, and it's going to regulators

Rocket shares promising long-term results from rare heart disease gene therapy in small study

FDA offers more guidance on developing cell and gene therapies

A rare neurological disease is Sage’s last, best hope after failures in depression

Are programs with compounded GLP-1s safe for your population?

US spe­cial coun­sel looks in­to al­leged mis­con­duct at Mer­ck plant prep­ping to make J&J shot — and in­dif­fer­ence from FDA

Josh Sullivan

Sign up to read this article for free.

Ex­clu­sive: Athena Coun­tou­ri­o­tis' Aven­zo taps Shang­hai biotech for ADC, adds new funds

Mer­ck fi­nal­ly has sub­cu­ta­neous Keytru­da re­sults, and it's go­ing to reg­u­la­tors

Rock­et shares promis­ing long-term re­sults from rare heart dis­ease gene ther­a­py in small study

FDA of­fers more guid­ance on de­vel­op­ing cell and gene ther­a­pies

A rare neu­ro­log­i­cal dis­ease is Sage’s last, best hope af­ter fail­ures in de­pres­sion

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

US special counsel looks into alleged misconduct at Merck plant prepping to make J&J shot — and indifference from FDA

Exclusive: Athena Countouriotis' Avenzo taps Shanghai biotech for ADC, adds new funds

Merck finally has subcutaneous Keytruda results, and it's going to regulators

Rocket shares promising long-term results from rare heart disease gene therapy in small study

FDA offers more guidance on developing cell and gene therapies

A rare neurological disease is Sage’s last, best hope after failures in depression

Are programs with compounded GLP-1s safe for your population?